Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy Omission with CDK4/6i in HR+/HER2- Node-Negative Breast Cancer
NCT06996093Phase 3Not yet recruiting
- Sponsor
- Fudan University
- Start
- Jun 2025
- Primary completion
- Jun 2030
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in breast cancer (2 arms), sponsored by Fudan University. Primary endpoint: Invasive Disease Free Survival at 4 years. Planned start Jun 2025; status: not yet recruiting.
02
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06996093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06996093.